Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 88NIH 15NETWORK 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 2

Conditions

Neutropenia 11Leukemia, Myeloid, Acute 9Breast Neoplasms 7Lymphoma, Non-Hodgkin 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Leukemia 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Plasmacytoma 2Paraproteinemias 2Pancreatic Neoplasms 2Neoplasms 2Leukemia, Plasma Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Febrile Neutropenia 2Anemia, Refractory, with Excess of Blasts 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neutropenia in Breast Cancer 1Myelodysplastic Syndromes 1Medulloblastoma 1

Interventions

Dexamethasone 306Bortezomib 159Lenalidomide 130pomalidomide 111daratumumab 93carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40elotuzumab 30belantamab mafodotin 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Injections 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × Filgrastim × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT02221479 2015-08-04

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Sanofi

Phase 2 Completed
14 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡